An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Agenmestencel-L (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 30 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 31 May 2016 Status changed from recruiting to active, no longer recruiting.
- 28 May 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.